Association Between Waiting Time from Diagnosis to Treatment and Survival in Patients with Curable Gastric Cancer: A Population-Based Study in the Netherlands by unknown
ORIGINAL ARTICLE – HEALTH SERVICES RESEARCH AND GLOBAL ONCOLOGY
Association Between Waiting Time from Diagnosis to Treatment
and Survival in Patients with Curable Gastric Cancer:
A Population-Based Study in the Netherlands
H. J. F. Brenkman, MD1 , E. Visser, MD1, P. S. N. van Rossum, MD, PhD1,2, S. Siesling, MD, PhD3,4,
R. van Hillegersberg, MD, PhD1, and J. P. Ruurda, MD, PhD1
1Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands; 2Department of Radiation
Oncology, University Medical Center Utrecht, Utrecht, The Netherlands; 3Department of Research, Netherlands
Comprehensive Cancer Organisation, Utrecht, The Netherlands; 4Department of Health Technology and Services
Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede,
The Netherlands
ABSTRACT
Background. In the Netherlands, a maximum waiting
time from diagnosis to treatment (WT) of 5 weeks is rec-
ommended for curative cancer treatment. This study aimed
to evaluate the association between WT and overall sur-
vival (OS) in patients undergoing gastrectomy for cancer.
Methods. This nationwide study included data from
patients diagnosed with curable gastric adenocarcinoma
between 2005 and 2014 from the Netherlands Cancer
Registry. Patients were divided into two groups: patients
who received neoadjuvant therapy followed by gastrec-
tomy, or patients who underwent gastrectomy as primary
surgery. WT was analyzed as a categorical (B5 weeks
[Reference], 5–8 weeks, [8 weeks) and as a discrete
variable. Multivariable Cox regression analysis was used to
assess the influence of WT on OS.
Results. Among 3778 patients, 1701 received neoadjuvant
chemotherapy followed by gastrectomy, and 2077 under-
went primary gastrectomy. In the neoadjuvant group,
median WT to neoadjuvant treatment was 4.6 weeks (in-
terquartile range [IQR] 3.4–6.0), and median OS was
32 months. In the surgery group, median WT to surgery
was 6.0 weeks (IQR 4.3–8.4), and median OS was
25 months. For both groups, WT did not influence OS
(neoadjuvant: 5–8 weeks, hazard ratio [HR] 0.82,
p = 0.068;[8 weeks, HR 0.85, p = 0.354; each additional
week WT, HR 0.96, p = 0.078; surgery: 5–8 weeks, HR
0.91, p = 0.175; [8 weeks, HR 0.92, p = 0.314; each
additional week WT, HR 0.99, p = 0.264).
Conclusions. Longer WT until the start of curative treat-
ment for gastric cancer is not associated with worse OS.
These results could help to put WT into perspective as
indicator of quality of care and reassure patients with
gastric cancer.
Gastric cancer is the fifth most common type of cancer
worldwide.1 In the Netherlands, only a third of patients
with gastric cancer qualify for curative treatment, which
consists of surgical resection with D2 lymphadenectomy
with or without perioperative chemotherapy.2,3 Unfortu-
nately, the 5-year overall survival (OS) after curative
treatment remains poor (35–45%).3–5
The interval from diagnosis to treatment (waiting time,
WT) is considered to be an important quality indicator for
cancer care because it negatively influences patients’
quality of life, results in psychologic distress, and has been
demonstrated to be associated with oncologic outcomes in
various cancers.6–8 Hence, in the Netherlands, WT to the
start of curative treatment for gastric cancer is an important
quality indicator as recommended by the Dutch Hospitals
Association, the Dutch Federation of University Medical
Centres, the Ministry of Health, Welfare and Sport, and the
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Association of Surgical Oncologists.6,9,10 However, the
biology and behavior of tumors vary, indicating that the
impact of WT for each type of cancer may differ. There-
fore, there is a need for cancer-specific recommendations.
Only one study has reported on this topic for gastric cancer
specifically.11 This study was performed in the Asian pop-
ulation, which differs significantly from the Western
population and generally does not undergo neoadjuvant
treatment.11,12 The aim of the current study was to evaluate
the association between WT and OS in a large Western
population-based cohort of patients undergoing curative
gastrectomy with or without perioperative chemotherapy for
cancer. It was hypothesized that longer WTs are associated
with worse OS as a result of disease progression.
MATERIALS AND METHODS
Study Design
This population-based cohort study was conducted with
data from the Netherlands Cancer Registry (NCR). In the
Netherlands, a population of 17 million inhabitants, all
newly diagnosed cancers are registered in the NCR, which
is hosted by the Netherlands Comprehensive Cancer
Organisation (IKNL). The main source of notification is the
National Automated Pathology Archive, which sends
weekly notifications of all cancer cases. Furthermore,
yearly, the National Registry of Hospital Discharge Diag-
noses is linked to the NCR to obtain clinical cancer
diagnosis only. On a daily basis, trained data managers
register data from hospital records within all Dutch hos-
pitals using the NCR’s registration and coding manual. The
privacy committee of the NCR approved this study.
Patient Population
In this study, all patients diagnosed with curable gastric
adenocarcinoma (cT1–4a, N0–3, M0) in the period
2005–2014 were selected from the NCR. Exclusion criteria
consisted of neoadjuvant therapy other than chemotherapy
and emergency gastrectomy (gastrectomy B14 days after
diagnosis or start of neoadjuvant treatment). Patients who
were diagnosed with curable gastric cancer (cTNM) but
who underwent a palliative resection (pTNM) were delib-
erately included in this study, as this might reflect disease
progression during WT.
Disease was staged, and patients underwent treatment
according to the nationwide guidelines for gastric cancer.2
Staging consisted of a gastroscopy and a computed tomo-
graphic scan in all patients, whereas endoscopic ultrasound
and diagnostic laparoscopy were not routinely performed.
Before 2006, the standard of treatment consisted of
gastrectomy only, and after that, an increasing number of
patients underwent perioperative chemotherapy.3 Surgery
consisted of a distal or total gastrectomy, depending on the
possibility to achieve an adequate proximal resection
margin (C6 cm), along with a D2 lymphadenectomy
(without station 10 dissection and without pancreaticos-
plenectomy).13,14 The resected specimens were reviewed
by pathologists and presented according to the American
Joint Committee on Cancer tumor, node, metastasis clas-
sification system (TNM) staging system (7th edition).
Statistical Analysis and Outcome Measures
All included patients were divided into two groups: a
neoadjuvant group and a surgery group. Patients in the
neoadjuvant group received neoadjuvant chemotherapy (as
part of perioperative chemotherapy) followed by gastrec-
tomy, whereas patients in the surgery group underwent
gastrectomy only. The WT was calculated in weeks and
was defined as the interval between the date of diagnosis
and the start date of neoadjuvant chemotherapy for the
neoadjuvant group, and as the interval between the date of
diagnosis and the date of gastrectomy for the surgery
group. The date of diagnosis was used as the date of the
first gastrointestinal endoscopy, on which the diagnosis of
gastric cancer had been established by histology from
biopsy samples. The WT constitutes a combination of time
needed to confirm the diagnosis of gastric cancer, referral
time, staging, pretherapeutic assessment, and actual WT for
treatment.2 WT was grouped into three categories of
B5 weeks, 5–8 weeks, and [8 weeks on the basis of
national recommendations and previous studies.6,15,16 In
both groups, a subgroup was made of patients who
underwent a curative gastrectomy (pT1–4aN ? M0) and
palliative gastrectomy (detected unresectable tumor [pT4b]
and/or metastatic disease [M1] intraoperatively). Missing
baseline data were considered at random and handled using
multiple imputation with the iterative Markov chain Monte
Carlo methods (20 iterations).
To assess the association between WT and tumor pro-
gression, the median WT was compared between the
curative and palliative treated patients by the Mann–
Whitney U test. To assess the distribution of all baseline,
surgical, and histopathologic characteristics in the different
WT groups (B5, 5–8,[8 weeks), all baseline, surgical, and
histopathologic characteristics were compared among the
three groups of WT. Categorical variables were analyzed
by the Chi square test, and continuous variables were
compared by the parametric ANOVA test.
To assess the association between WT and OS, uni-
variable and multivariable analyses by means of Cox
proportional hazard models were used, providing hazard
ratios (HRs) with 95% confidence intervals. WT was
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analyzed as a categorical variable and as a discrete vari-
able. All baseline variables and WT were entered in a
multivariable analysis. Sensitivity analyses were performed
for the following subgroups: cT1–2 versus cT3–4, good to
moderate versus poor to undifferentiated tumors, and cN0
versus cN?. OS was defined as the time from the start date
of treatment to the date of death from any cause or to the
date of last follow-up (December 2015). A p value of
\0.05 was considered statistically significant. All statisti-




The NCR selected data from 4088 patients diagnosed
with curable gastric adenocarcinoma (2005–2014). A total
of 310 patients were excluded because of neoadjuvant
therapy other than chemotherapy (n = 30) and emergency
gastrectomy (n = 280). Of the remaining 3778 patients,
1701 received neoadjuvant chemotherapy followed by
gastrectomy, and the other 2077 patients underwent pri-
mary gastrectomy.
Baseline characteristics of the neoadjuvant group are
presented in Table 1. The mean age was 62.6 years, most
of the patients were male (n = 1064, 63%), and most were
clinically staged as having cT1–2 (n = 483, 55%) and cN0
(n = 951, 65%) disease. The majority underwent a distal
gastrectomy (n = 924, 54%) and an open surgical
approach (n = 1447, 86%). A curative gastrectomy was
performed in 1544 patients (92%). The other 127 patients
(8%) received a palliative resection (pT4b or pM1
intraoperatively).
Baseline characteristics of the surgery group data are
presented in Table 2. The mean age was 73.5 years, most
of the patients were male (n = 1253, 60%), and most were
clinically staged as having cT1–2 (n = 486, 67%) and cN0
(n = 1326, 77%) disease. The majority underwent a distal
gastrectomy (n = 1435, 69%) and an open approach
(n = 1908, 94%). A curative gastrectomy was performed
in 1946 patients (94%), and a palliative resection (pT4b or
pM1 intraoperatively) was performed in 120 patients (6%).
WT and Related Variables
The WT to neoadjuvant therapy was missing in 215
patients (13%), the result of an unknown start date for
neoadjuvant treatment. Median WT was 4.6 weeks (in-
terquartile range [IQR] 3.4–6.0). The median WT did not
significantly differ between the curative (pT1–4a, N0–3,
M0) and palliative (pT4b and/or pM1) treated patients (4.6
vs. 4.1 weeks, p = 0.136). The groups of B5 weeks,
5–8 weeks, and [8 weeks consisted of 895 (60%), 451
(30%), and 140 (9%) patients, respectively (Table 1). The
only difference with regard to baseline characteristics
included referral status (p\ 0.001). Surgical and
histopathologic characteristics differed on ypT stage
(p\ 0.001), ypN stage (p = 0.036), and adjuvant therapy
(p = 0.009). Patients with pathologic advanced tumor
stages had significantly shorter WTs compared to patients
with early tumor stages.
In the surgery group, the WT was available in all 2077
patients. Median WT was 6.0 weeks (IQR 4.3–8.4). The
median WT was significantly longer in the curative-treated
patients compared to the palliative-treated patients (6.1 vs.
5.1 weeks, p = 0.005). The groups of B5 weeks,
5–8 weeks, and [8 weeks consisted of 772 (37%), 727
(35%), and 578 (28%) patients, respectively (Table 2). Age
(p\ 0.001), tumor differentiation (p = 0.008), cT stage
(p\ 0.001), cN stage (p\ 0.001), year of diagnosis
(p\ 0.001), and referral status (p\ 0.001) all significantly
differed between the groups. Most importantly, patients
with clinical advanced tumor stages had a significantly
shorter WT to gastrectomy compared to patients with early
tumor stages. Furthermore, WT increased over the years
both in the categorized WT groups (Table 2) as in median
WT (2006–2008: 5.4 weeks; 2009–2011: 6.6 weeks;
2012–2014: 6.7 weeks). Regarding surgical and
histopathologic characteristics, surgical type (p = 0.008),
surgical approach (p = 0.002), radicality (p = 0.003), pT
stage (p\ 0.001), pN stage (p\ 0.001), curative intent
(p = 0.035), and adjuvant therapy (p = 0.043) differed
significantly between the WT groups. Patients who
underwent an irradical resection or a resection for patho-
logic advanced tumor stages had significantly shorter WTs.
Overall Survival
Median OS in the neoadjuvant group was 32 months
(range 1–118 months), and 1-, 3-, and 5-year survival rates
were 86, 58, and 47%, respectively. The categorized and
linear effect of WT on OS is presented in Table 3. In
multivariable analysis, both the categorized and the dis-
crete variables of WT were not identified as independent
prognostic factors associated with OS (WT 5–8 weeks vs.
B5 weeks, HR 0.82, p = 0.68; [8 weeks vs. B5 weeks,
HR 0.85, p = 0.354; and additional week WT, HR 0.96,
p = 0.065).
Median OS in the surgery group was 25 months (range
0–120 months), and 1-, 3-, and 5-year survival rates were
73, 46, and 37%, respectively. The categorized and linear
effect of WT on OS is presented in Table 3. In multivari-
able analyses, both the categorized and discrete variables
of WT were not identified as independent prognostic fac-
tors associated with OS (WT 5–8 weeks vs. B5 weeks, HR
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TABLE 1 Baseline, surgical, and histopathologic characteristics of 1701 patients treated with neoadjuvant chemotherapy followed by gas-
trectomy for cancer
Characteristic All (N = 1701) \5 weeks (n = 895) 5–8 weeks (n = 451) [8 weeks (n = 140) p
n % n (%) n (%) n (%)
Baseline characteristics
Age, year, mean (±SD) 62.6 (±10.6) 62.4 (10.7) 63.2 (10.5) 62.4 (9.0) 0.386
Gender 0.479
Male 1064 (63) 548 (59) 287 (31) 92 (10)
Female 637 (37) 347 (62) 164 (29) 48 (9)
Malignancy history 0.934
No 1546 (91) 814 (60) 409 (30) 126 (9)
Yes 155 (9) 81 (59) 42 (31) 14 (10)
Tumor differentiation 0.163
Good to moderate 202 (20) 110 (21) 44 (17) 19 (26)
Poor to undifferentiated 798 (80) 403 (79) 217 (83) 55 (74)
Missing 701 382 190 66
cT stage 0.399
T1 44 (5) 22 (55) 12 (30) 6 (15)
T2 439 (50) 235 (56) 138 (33) 45 (11)
T3 304 (35) 158 (55) 97 (34) 30 (11)
T4a 88 (10) 33 (45) 26 (36) 14 (19)
Tx 826 447 178 45
cN stage 0.466
N0 951 (65) 504 (58) 277 (32) 82 (10)
N? 511 (35) 285 (62) 134 (29) 42 (9)
Nx 239 106 40 16
Year of diagnosis 0.268
2006–2008 356 (21) 120 (59) 57 (28) 28 (14)
2009–2011 616 (36) 339 (61) 170 (30) 49 (9)
2012–2014 729 (43) 436 (60) 224 (31) 63 (9)
Referral status \0.001
Diagnosis in treatment hospital 1009 (69) 536 (53) 233 (23) 64 (6)
Diagnosis in other hospital 445 (31) 211 (47) 144 (32) 53 (12)
Missing 247 148 74 23
Treatment and histopathologic characteristics
Surgical type 0.687
Distal gastrectomy 924 (54) 487 (61) 236 (30) 77 (10)
Total gastrectomy 749 (44) 394 (59) 211 (32) 62 (9)
Multiorgan surgery 28 (2) 14 (74) 4 (21) 1 (5)
Surgical approach 0.679
Open 1447 (86) 742 (60) 373 (30) 119 (10)
Laparoscopic 230 (14) 141 (62) 69 (30) 18 (8)
Missing 24 12 9 3
Radicality 0.782
R0 1405 (86) 738 (60) 368 (30) 116 (9)
R1–2 239 (15) 129 (61) 66 (31) 17 (8)
Missing 57 28 17 7
ypT stage \0.001
T0 112 (7) 56 (57) 37 (37) 6 (6)
T1 236 (14) 96 (48) 69 (34) 36 (18)
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0.91, p = 0.175; [8 weeks vs. B5 weeks, HR 0.92,
p = 0.314; and additional week WT, HR 0.99, p = 0.264).
Sensitivity analyses did not significantly change the HR
estimates of the original multivariable analyses.
DISCUSSION
This population-based cohort study examined whether
WT between diagnosis and start of treatment with curative
intent was associated with OS in patients with gastric
cancer. The results demonstrated that WT was not associ-
ated with OS in either patients treated with neoadjuvant
chemotherapy or primary gastrectomy. The study is novel
in that it is the first to be conducted in the West and the first
to evaluate the association of WT between diagnosis and
the start of neoadjuvant therapy, which has become the
standard of care.
This study was conducted with the hypothesis that
longer WTs might lead to a worse OS through disease
progression, as has been shown for breast cancer, uterine
cancer, and head and neck cancer.17–19 For lung cancer,
pancreatic head cancer, colorectal cancer, and esophageal
cancer, however, studies could not demonstrate this rela-
tionship.8,14,20–22 For gastric cancer specifically, a previous
study reported that a longer WT did not adversely affect
survival.11 Unfortunately, this study did not investigate the
WT between diagnosis and the start of neoadjuvant treat-
ment, and it was conducted in an Asian population, which
differs significantly from a Western population.12 The
results of the present study are therefore reassuring and
confirm that WT does not adversely affect survival. The
varying impact of WT for different cancer types may be
explained by differences in duration of patient delay and
diagnostic delay. The variety of these delays between
cancer types may be related to the cancer site, time of
manifestation of symptoms, and presence or absence of
screening programs. Compared to these delays (months to
years), WT from diagnosis to treatment (weeks to months)
is relatively short and may have a negligible effect on OS,
as this study demonstrated for gastric cancer.23
Interestingly, this study found that in both groups,
patients with pathologic advanced tumor stages had shorter
TABLE 1 continued
Characteristic All (N = 1701) \5 weeks (n = 895) 5–8 weeks (n = 451) [8 weeks (n = 140) p
n % n (%) n (%) n (%)
T2 256 (15) 142 (62) 67 (29) 20 (9)
T3 700 (42) 385 (62) 186 (30) 48 (8)
T4a 309 (19) 162 (62) 73 (28) 25 (10)
T4b 57 (3) 39 (74) 11 (21) 3 (6)
Tx 31 15 8 2
ypN stage 0.036
N0 805 (47) 387 (55) 234 (33) 80 (11)
N1 338 (20) 193 (67) 78 (27) 19 (7)
N2 274 (16) 147 (63) 64 (28) 21 (9)
N3 282 (17) 168 (64) 75 (29) 20 (8)
Nx 2
ypM stage 0.357
M0 1625 (96) 885 (61) 438 (30) 135 (9)
M1 76 (5) 40 (69) 13 (22) 5 (9)
Curative intent 0.112
Yes 1544 (92) 807 (57) 419 (30) 188 (13)
No 127 (8) 74 (62) 24 (20) 21 (18)
Missing 30 14 8 6
90-day mortality 69 (4) 40 (4) 12 (3) 7 (5) 0.223
Adjuvant therapy 0.009
No 724 (43) 371 (59) 200 (32) 62 (10)
Chemotherapy 783 (46) 429 (64) 185 (27) 61 (9)
Radiotherapy 5 (\1) 2 (50) 0 (0) 2 (50)
Chemoradiation 189 (11) 93 (53) 66 (38) 15 (9)
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TABLE 2 Baseline, surgical and histopathologic characteristics of 2077 patients treated with primary gastrectomy for cancer
Characteristic All (N = 2077) \5 weeks (n = 772) 5–8 weeks (n = 727) [8 weeks (n = 578) p
n (%) n (%) n (%) n (%)
Baseline characteristics
Age, year, mean (±SD) 73.5 (±10.1) 73.2 (10.4) 74.6 (8.9) 72.3 (11.1) \0.001
Gender 0.345
Male 1253 (60) 461 (37) 429 (34) 363 (29)
Female 824 (40) 311 (38) 298 (36) 215 (26)
Malignancy history 0.393
No 1745 (84) 659 (38) 608 (35) 478 (27)
Yes 332 (16) 113 (34) 119 (36) 100 (30)
Tumor differentiation 0.008
Good to moderate 582 (34) 212 (31) 197 (33) 173 (40)
Poor to undifferentiated 1131 (66) 467 (69) 404 (67) 260 (60)
Missing 364 93 126 145
cT stage \0.001
T1 139 (19) 24 (17) 37 (27) 78 (56)
T2 347 (48) 120 (35) 133 (38) 94 (27)
T3 150 (21) 57 (38) 50 (33) 43 (29)
T4a 84 (12) 45 (54) 24 (29) 15 (18)
Tx 1357 526 483 348
cN stage \0.001
N0 1326 (77) 440 (33) 483 (36) 403 (30)
N? 387 (23) 181 (47) 136 (35) 70 (18)
Nx 364 151 108 105
Year of diagnosis \0.001
2006–2008 934 (45) 426 (46) 308 (33) 200 (21)
2009–2011 608 (29) 187 (31) 220 (36) 201 (33)
2012–2014 535 (26) 159 (30) 199 (37) 177 (33)
Referral status \0.001
Diagnosis in treatment hospital 1657 (86) 674 (41) 585 (35) 398 (24)
Diagnosis in other hospital 262 (14) 60 (23) 81 (31) 121 (46)
Missing 158 38 61 59
Treatment and histopathologic characteristics
Surgical type 0.008
Distal gastrectomy 1435 (69) 545 (38) 501 (35) 389 (27)
Total gastrectomy 607 (29) 206 (34) 215 (35) 186 (31)
Multiorgan surgery 35 (2) 21 (60) 11 (31) 3 (9)
Surgical approach 0.002
Open 1908 (94) 728 (38) 671 (35) 509 (27)
Laparoscopic 129 (6) 33 (26) 45 (35) 51 (40)
Missing 40 11 11 18
Radicality 0.003
R0 1689 (85) 595 (35) 599 (35) 495 (29)
R1–2 291 (15) 126 (43) 106 (36) 59 (20)
Rx 97 51 22 24
pT stage \0.001
T1 454 (22) 89 (20) 156 (34) 209 (46)
T2 321 (16) 104 (32) 121 (38) 96 (30)
T3 747 (36) 321 (43) 259 (35) 167 (22)
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WTs than patients diagnosed with pathologic early tumor
stages. In the surgery group, this difference was already
present at baseline, and therefore, it is assumed that
patients with clinical advanced tumor stages may have had
priority and may have been scheduled for surgery earlier.
On the other hand, it can be hypothesized that some
patients with clinical advanced tumor stages with a long
WT may have developed disease progression as a result of
TABLE 2 continued
Characteristic All (N = 2077) \5 weeks (n = 772) 5–8 weeks (n = 727) [8 weeks (n = 578) p
n (%) n (%) n (%) n (%)
T4a 489 (24) 234 (48) 166 (34) 89 (18)
T4b 55 (3) 23 (42) 21 (38) 11 (20)
Tx 11 1 4 6 \0.001
pN stage
N0 995 (48) 291 (29) 346 (35) 358 (36)
N1 347 (17) 137 (39) 127 (37) 83 (24)
N2 336 (16) 146 (43) 121 (36) 69 (21)
N3 390 (19) 193 (49) 130 (33) 67 (17)
Nx 9 5 3 1
pM stage 0.162
M0 2003 (96) 737 (37) 707 (35) 559 (28)
M1 74 (4) 35 (47) 20 (27) 19 (26)
Curative intent 0.035
Yes 1946 (94) 713 (37) 687 (35) 546 (28)
No 120 (6) 58 (48) 36 (30) 26 (22)
Missing 11 1 4 6
90-day mortality 240 (12) 94 (12) 68 (9) 78 (13) 0.053
Adjuvant therapy 0.043
No 1993 (96) 730 (37) 704 (35) 559 (28)
Chemotherapy 28 (1) 11 (39) 6 (21) 11 (39)
Radiotherapy 1 (\1) 1 (100) 0 (0) 0 (0)
Chemoradiation 55 (3) 30 (55) 17 (31) 8 (15)
TABLE 3 Univariable and multivariable Cox proportional hazard analysis on influence of WT on risk of death in patients treated with
neoadjuvant chemotherapy followed by gastrectomy or primary gastrectomy for cancer
Characteristic Univariable Multivariablea
HR (95% CI) p HR (95% CI) p
Neoadjuvant treatment
WT B5 weeks Ref – Ref –
WT 5–8 weeks 0.79 (0.67–0.94) 0.008* 0.82 (0.66–1.02) 0.068
WT[8 weeks 0.80 (0.62–1.05) 0.106 0.85 (0.59–1.21) 0.354
Additional week WT 0.97 (0.94–1.01) 0.057 0.96 (0.92–1.00) 0.078
Surgery only
WT B5 weeks Ref – Ref –
WT 5–8 weeks 0.86 (0.76–0.98) 0.018* 0.92 (0.81–1.05) 0.200
WT[8 weeks 0.75 (0.65–0.86) \0.001* 0.95 (0.79–1.08) 0.314
Additional week WT 0.97 (0.96–0.99) \0.001* 0.99 (0.98–1.01) 0.264
CI confidence interval, HR hazard ratio, WT waiting time
* Statistically significant (p\ 0.05)
a Adjusted for baseline characteristics: age, gender, malignancy history, tumor differentiation, cT stage, cN stage, year of diagnosis, and referral
status
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this longer WT and eventually may have dropped out for
surgery, and hence were not included in this study.
Unfortunately, these dropouts could not be extracted from
the NCR. Because both dropouts and palliative gastrec-
tomies are due to disease progression, it is unlikely that
there is a significant amount of dropouts with longer WTs.
Because this study did not show a clinically relevant dif-
ference in WT between curative resections and palliative
resections, we assume that dropouts were not likely to have
affected the results significantly. In the neoadjuvant group,
it remains unclear why patients with pathologic advanced
tumor stages had shorter WTs. Early treatment due to
worse tumor characteristics seems unlikely, as cTN stages
were comparable between the WT groups, and moreover,
no waiting list exists for the start of neoadjuvant
chemotherapy in the Netherlands. Although median WTs
in the palliative group did not exceed the median WTs in
the curative group (both around 4 weeks), longer WTs
might have caused dropouts, which resulted in patient
selection. Furthermore, a discrepancy in clinical and
pathologic tumor stages should be interpreted with caution
for two reasons. First, imaging strategies currently used for
clinical TN staging all have their specific limitations, and
accurate prediction of pathologic TN stage is still not
possible for an individual patient.24 Second, neoadjuvant
chemotherapy downsizes the tumor and influences patho-
logic tumor stages.
In more recent years, WT to primary surgery increased,
whereas WT to neoadjuvant therapy remained stable. We
assume that this can be explained by the fact that most
patients who underwent primary surgery after 2008 were
not eligible for perioperative chemotherapy—for instance,
as a result of poor condition. It is expected that in these
patients, more time was needed to optimize them before the
start of treatment. Moreover, patients treated with primary
surgery needed more referral in the recent years (data not
shown). Because additional time is needed for referral, the
WT may have increased in this group.
In the Netherlands, WT is seen as an important quality
indicator by several authorities.9,10 This study demonstrated
that 57% of the patients who underwent neoadjuvant treat-
ment, and 37% of the patients who underwent primary
surgery, comply with this recommendation. For gastric
cancer, this study demonstrated that there is no absolute need
to strictly adhere to this recommendation for oncologic
reasons. Factors such as patient delay and delay to diagnosis
are probably more relevant for oncologic outcomes, as these
time frames are relatively longer than the WT from diagnosis
to treatment.23 Because WT does not impair oncologic out-
comes within a clinically relevant time frame, it may be used
to optimize these often malnourished patients before the start
of the intensive treatment.25 In fact, optimizing patients
could be an explanation for the fact that many patients were
not treated within 5 weeks in our cohort. On the other hand,
WT can have a negative (psychosocial) influence on patient
factors such as quality of life.7 Efforts should therefore be
made to keep the WT to a minimum. During WT, the results
from this study can be used to reduce psychosocial distress
by reassuring patients that longer WTs do not adversely
affect oncologic outcomes.
This study has some limitations. First, although we
adjusted for most of the generally accepted baseline char-
acteristics in gastric cancer, other potential confounding
factors may have been missed. For instance, data on
patients’ comorbidities, performance status, or nutritional
status, symptoms of the tumor, and hospital factors were
not available from the NCR database, but these data might
have influenced the results. Second, although data from the
NCR are being directly extracted from medical records
within 9 months after diagnosis, the study was retrospec-
tive in nature, and possible confounders may have been
missed. On the other hand, a randomized trial would not be
ethical to evaluate the influence of WTs. Therefore, mul-
tivariable analysis as performed in this study will remain
one of the best methods to investigate this topic.
Nonetheless, this is the first nationwide cohort study
investigating the effect of WT on survival in patients with
gastric cancer in the West. The results of this study can be
extrapolated to other countries in the West because treat-
ment and outcomes of gastric cancer care are comparable
and therefore can be used for the composition of (inter-
national) guidelines on gastric cancer treatment.26
In conclusion, this large population-based cohort study
demonstrated that a longer WT between diagnosis and start
of treatment with curative intent for gastric cancer is not
associated with worse OS. Although efforts should be
made to keep WT to a minimum for patients’ quality of
life, these results could help establish new cancer-specific
guidelines and reassure patients with gastric cancer.
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